Asset Details
Do you wish to reserve the book?
Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy
Do you wish to request the book?
Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dual function antibody targeting αvβ3 and PD-L1 provide a promising strategy for solid tumor therapy
2026
Overview
The inhibition of the PD-1/PD-L1 axis has exhibited significant advancements in cancer immunotherapy, improving patient outcomes in various cancers. However, the clinical efficacy of these monotherapies remains limited in many cases. Integrin αvβ3 has been identified as a positive regulator of PD-L1 expression and a critical contributor to cancer immune evasion. To address this, we developed a dual function antibody, B1451, that recognizes both PD-L1 and αvβ3 and evaluated its antitumor efficacy in pre-clinical models
and
.
We first analyzed the correlation between PD-L1 and αvβ3 expression, as well as the role of αvβ3 in modulating sensitivity to immunotherapy, using the TISIDB database. Subsequently, we designed and constructed a dual function PD-L1×αvβ3 antibody (B1451) by conjugating an integrin αvβ3-binding peptide to the C-terminal of the heavy chain of the anti-PD-L1 monoclonal antibody, Atezolizumab, using a (G4S)×3 linker. The antitumor efficacy of B1451 was then evaluated in preclinical models
and
.
Our findings demonstrated a significant positive correlation between the gene expression of PD-L1 and αvβ3 across various human solid tumors. Additionally, high αvβ3 expression appears to influence the sensitivity to immunotherapy. The dual function antibody B1451 was capable of recognizing human PD-L1 and αvβ3 antigens, effectively blocking both the PD-1/PD-L1 and vitronectin/αvβ3 pathways. B1451 inhibited tumor cell migration, adhesion, and angiogenesis
, and exhibited superior anti-tumor activity
than monotherapy.
The dual function antibody targeting both αvβ3 and PD-L1 holds the potential to reverse immune evasion and exhibit synergistic anti-tumor effects, offering a promising therapeutic strategy for the treatment of solid tumor.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Animals
/ Antibodies, Monoclonal - pharmacology
/ Antibodies, Monoclonal, Humanized - pharmacology
/ antibody
/ Antigens
/ B7-H1 Antigen - antagonists & inhibitors
/ Female
/ Genes
/ Humans
/ Immune Checkpoint Inhibitors - pharmacology
/ Integrin alphaVbeta3 - antagonists & inhibitors
/ Integrin alphaVbeta3 - immunology
/ Integrin alphaVbeta3 - metabolism
/ Mice
/ PD-L1
/ Peptides
/ Proteins
/ Tumors
/ Xenograft Model Antitumor Assays
/ αvβ3
